Holdings

Symbol Grade Price % Change Allocation
NVO F -0.01 2.06
NVS D 0.88 1.30
RY B 0.74 1.12
ABBV A -0.16 1.11

Recent News for iShares Paris-Aligned Climate MSCI World ex USA ETF & its Holdings

Date Stock Title
Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
Nov 1 ABBV Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Nov 1 ABBV Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
Nov 1 NVS Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
Nov 1 NVS Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
Nov 1 NVS Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Nov 1 ABBV AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Nov 1 RY RBC to announce fourth quarter and fiscal 2024 results
Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
Nov 1 ABBV AbbVie and EvolveImmune Therapeutics sign oncology collaboration
Nov 1 ABBV 5 Stocks That Recently Announced Dividend Hikes
Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
Nov 1 ABBV Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Nov 1 ABBV Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
The index is composed of large- and mid-cap developed market equities, excluding the U.S., that are selected and weighted so that, in the aggregate, the portfolio is compatible with the objectives of the Paris Agreement by following a decarbonization trajectory, reducing exposure to climate-related transition and physical risks and increasing exposure to companies favorably positioned for the transition to a low-carbon economy. The fund generally will invest at least 90% of its assets in the component securities of its index.
Passive Management
Back to the Main PABD Page...